Signant’s Endpoint Reliability and eCOA Solutions Facilitate CNS Trial Success

Date Published:
Case Study

A Japan-based, global pharmaceutical development company leveraged Signant’s eCOA solutions and expertise to ensure endpoint reliability for their phase 3 and long-term extension CNS trials. The trials entailed several complexities related to the quantity and nature of the clinical outcome assessments (COAs) and rating instruments used to support the primary endpoint.

As established leaders in global CNS trial optimization, Signant was prepared with the ideal tools and expertise, providing the study teams with:

  • COA selection, acquisition, translation, and implementation services
  • A customized rater training and certification program including on-demand video
  • Central rating and expert clinical review services

Find out how these solutions and Signant’s expertise impacted trial outcomes in this case study.

Learn More